Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives

Sclerostin emerges as a novel target for bone anabolic therapy in bone diseases. Osteogenesis imperfecta (OI) and X-linked hypophosphatemia (XLH) are rare bone diseases in which therapeutic potential of sclerostin inhibition cannot be ignored. In OI, genetic/pharmacologic sclerostin inhibition promo...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Tao Xiaohui, Luyao Wang, Xin Yang, Hewen Jiang, Ning Zhang, Huarui Zhang, Dijie Li, Xiaofei Li, Yihao Zhang, Shenghang Wang, Chuanxin Zhong, Sifan Yu, Meishen Ren, Meiheng Sun, Nanxi Li, Tienan Chen, Yuan Ma, Fangfei Li, Jin Liu, Yuanyuan Yu, Hua Yue, Zhenlin Zhang, Ge Zhang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-07-01
Edice:	Journal of Orthopaedic Translation
Témata:	Cardiovascular safety Loops Osteogenesis imperfecta (OI) Sclerostin Sclerostin inhibition Therapeutic perspectives
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2214031X24000469
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!